BridgeBio Pharma Posts Narrower Net Loss on Revenue Growth
BridgeBio Pharma, a commercial-stage company, reported narrower net loss for its fourth quarter due to revenue growth from improved product sales. The company’s total quarterly revenue increased to $154.18 million, driven by a significant increase in net product revenue from Attruby. For the full year 2025, BridgeBio’s net loss widened to $724.93 million, despite revenue … Read more